Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Why 2017 AAOA Advanced Course in Allergy & Immunology

By Cecelia Damask, DO, Director of Educational Programs Due to popular demand, the AAOA is excited…

read more

CMS Releases Proposed Physician Fee Schedule for CY 2018

AAOA had participated in surveys for the American Medical Association’s (AMA) Relative Value Update Committee…

read more

CMS Releases Quality Payment Program Proposed Rule

The Centers for Medicare and Medicaid Services (CMS) released a proposed rule outlining the requirements…

read more

Changes in MACRA

Macra 101 Image

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

The AMA continues to hear from physicians who feel unprepared to participate successfully in Medicare’s new Merit-based Incentive Payment System, despite the transitional flexibility provided for 2017.
Read More

Upcoming Dates

04/01/2018: Research Grant Cycle

10/01/2018: Research Grant Cycle
Learn more

07/31/18: Membership Application Deadline to be voted in at the 2018 Annual Meeting
Learn more

EDUCATION

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Updated Advanced Course

Drs. Damask and Parker will lead the faculty for our annual Advanced Course in Allergy & Immunology that builds on the Basic Course and delves further into allergy diagnosis, management, and treatment.
Read More

Interactive Allergy & Rhinology Course

Course directors, Christine Franzese and Sarah Wise, are excited to announce the 2018 AAOA Interactive Allergy and Rhinology Course.
Read More

IFAR

aaoaf-ifar

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2017 Advanced Course in Allergy & Immunology
December 6-9 | Vail, CO.
Learn more and Register

2018 Interactive Allergy & Rhinology Course
February 23-25 | Dallas, TX
Learn More and Register

2018 Basic Course in Allergy & Immunology
July 5-7 | Hollywood, FL
Save the Date

2018 AAOA Annual Meeting
September 14-16 | Philadelphia, PA
Save the Date

Clinical Insights With Wiley
Start Learning Now

PATIENT CORNER

Avoidance

The first most basic treatment step, once an allergen has been identified, is to eliminate or avoid contact with it, if possible. Unfortunately, avoiding some allergens (such as dust, molds, and animals) is often difficult and thus allergen avoidance alone may not be effective.

Read More

News and Updates

Join me in Chicago at the Redesigned AAOA Annual Meeting

By Cecelia Damask, DO, Director of Educational Programs…

Read More

Practice Management

Strategies & Tactics to Improve Efficiencies for Better…

Read More

ReCAP — Review Of Core Allergy Principles

The AAOA Education Committee is pleased to…

Read More
Menu
Vials Of Allergens

Allergenic Extracts

In late November 2013, Congress passed the Compounding Bill. This legislation enforces regulation of compounding pharmacies, as a result of injections of contaminated compounded drugs – which caused 64 deaths and many more nonfatal injuries.

PLEASE NOTE: The preparation of allergenic extract vials is considered compounding. The AAOA is pleased that the new legislation does not restrict or limit the ability of Allergists to compound allergy vaccines. AAOA members may have to adopt additional measures to ensure sterility, based on USP guidelines, but fortunately the ability to continue compounding extracts remains.

The statute contains two provisions that may impact allergy immunotherapy. Since the law is effective, it is recommend that you implement these changes as soon as possible. The AAOA expects practices will be subject to inspections to monitor compliance.

The first requirement is that all compounded sterile preparations have a prescription. This should not cause much of a problem since most AAOA members already have an order sheet of some sort, which is used to instruct staff to make a new or renewal vial for a patient. These order sheets can be labeled at the top as a prescription for a specific patient, and they can have a line at the bottom for the physician’s (or other appropriately licensed provider’s) signature. Again, you are already signing off on this process, as well as the shots, so this should not be a huge practice change.

In addition, it appears that physicians will be required to comply with all of the USP 797 sterile compounding rules. Fortunately, because of work by the AAOA in conjunction with JCAAI back in 2006, USP 797 contains specific rules for allergy vaccine compounding that are much less stringent than the rules applicable to other compounded sterile products. While the USP rules are not draconian (no filtered air or laminar flow hoods required), they do increase the standard for sterility.You can read the relevant Allergy Section of USP 797 by clicking here or read the rules below.

“Allergen extracts, as compounded sterile preparations (CSPs), are single-dose and multiple dose intradermal or subcutaneous injections that are prepared by specially trained physicians and personnel under their direct supervision. Allergen extract, as CSPs, is not subject to the personnel environmental and storage requirements for all CSP microbial contamination risk levels in this chapter, BUT only if all of the following criteria are met:

  1. The compounding process involves simple transfer via sterile needles and syringes of commercial sterile allergen products and appropriate sterile added substances (e.g., Glycerin, phenol in sodium chloride injection).
  2. All allergen extract as CSPs shall contain appropriate substances in effective concentrations to prevent the growth of microorganisms. Non-preserved allergen extracts shall comply with the appropriate CSP risk level requirements in the chapter.
  3. Before beginning compounding activities, personnel perform a thorough hand cleansing procedure by removing debris from under fingernails using a nail cleaner under running warm water followed by vigorous hand and arm washing to the elbows for at least 30 seconds – with either non-antimicrobial or antimicrobial soap and water.
  4. Compounding personnel don hair covers, facial hair covers, gowns and face masks.
  5. Compounding personnel perform antiseptic hand cleansing with an alcohol – based surgical hand scrub with persistent activity.
  6. Compounding personnel don powder – free sterile gloves that are compatible with sterile 70% isopropyl alcohol (IPA) before beginning compounding manipulations.
  7. Compounding personnel disinfect their gloves intermittently with sterile 70% IPA when preparing multiple allergen extracts as CSPs.
  8. Ampule necks and vial stoppers on packages of manufactured sterile ingredients are disinfected by careful wiping with sterile 70% IPA swabs to ensure that the critical sites are wet for at least 10 seconds and allowed to dry before they are used to compound allergen extracts as CSPs.
  9. The aseptic compounding manipulations minimize direct contact contamination (e.g., from glove, fingertips, blood, nasal and oral secretions, shed skin and cosmetics, other non-sterile materials) of critical sites (e.g., needles, open ampules, vial stoppers).
  10. The label of each multiple-dose vial (MDV) of allergen extracts (as CSPs) lists the name of one specific patient, a “by use date” (BUD) and storage temperature range that is assigned based on manufacturers recommendations or peer-reviewed publications.
  11. Single-dose allergen extracts as CSPs shall not be stored for subsequent additional use.

Personnel who compound allergen extracts as CSPs, must be aware of greater potential risk of microbial and foreign material contamination when allergen extracts are compounded in compliance with the foregoing criteria instead of the more rigorous standards in the USP chapter for CSP microbial contamination risk levels. Although contaminated allergen extracts as CSPs can pose health risks to patients when they are injected intradermally or subcutaneously, these risks are substantially greater if the extract is inadvertently injected intravenously.”

References

1. Lay PC, Bass R, Lin SY. Allergen vial mixing and immunotherapy:  risks of infection and vial contamination.  Otolaryngol Head Neck Surg. 2007 Aug;137(2):243-5

2. Lin SY, Lay PC, Hughes LF, Bass R. The safety of multi-dose vials in allergy immunotherapy.  Otolaryngol Head Neck Surg. 2008 Aug;139(2):195-7

3. Lay PC, Bass R, Hughes LF, Lin SY. Risks of allergy vial contamination: Comparison of mixing in-office versus under ventilation hood. Otolaryngol Head Neck Surg. 2008 Sep;139(3):364-6.

4. Gilbert KC, Sundareshan V, Bass RM, Lin SY.  Antibacterial Properties of Additives Used in Injection Immunotherapy. Int Forum Allergy Rhinol.  2011 Dec 7. doi: 10.1002/alr.20105. [Epub ahead of print].

Leave a Reply

Your email address will not be published. Required fields are marked *